Nutritional Status and Sarcopenia in Patients with Non-Alcoholic Fatty Liver Disease at a Private Hospital in Coimbatore, India
Status Gizi dan Sarkopenia pada Pasien Penyakit Hati Berlemak Non-Alkohol di sebuah Rumah Sakit Swasta di Coimbatore, India
Background: The Global prevalence of sarcopenia was estimated as 10% to 27% among Non-Alcoholic Fatty Liver Disease (NAFLD) patients.
Objectives: To investigate the association between nutritional status and sarcopenia among NAFLD patients.
Methods: The study was conducted between January 2024 and June 2024 and included 218 study participants. The social and demographic profile, dietary habits, fatigue, and 24-hour recall dietary intake were assessed using the interview cum questionnaire. Bio Impendence Analysis (BIA) and a hand grip dynamometer were used to assess the MM and MS. Functional capacity was analysed using the 6-Minute Walk Test (6MWT).
Results: The relationship between relative risk factors and sarcopenia showed that male had a Relative Risk Ratio (RRR)=4.048 (95% CI: 1.073-15.275), overweight RRR=5.929 (95% CI: 1.42-24.763), Muscle Mass (MM) RRR=0.857 (95% CI: 0.741-0.99), Muscle Strength (MS) RRR=0.809 (95% CI: 0.729-0.898), Neutrophil-to-Lymphocyte Ratio (NLR) RRR=0.254 (95% CI: 0.069-0.933), moderate fatigue RRR=0.313 (95% CI: 0.107-0.921), 6MWT RRR=0.989 (95% CI: 0.981-0.996).
Conclusions: A reduction in MM, MS, and physical performance had shown a significant association with sarcopenia, indicating the reduction in these factors can lead to an increase in sarcopenia. Tailoring the intervention to increase the MM, strength, and physical performance can help in reducing the progression of sarcopenia and disease outcomes.
Terry, C. F., Wong, G. L., Wong, V. W., Goh, G. B. & Chan, W. K. Nonalcoholic fatty liver disease: a unique entity or part of the metabolic syndrome or both. Med. Clin. North Am. 2023, https: //doi.org/10.1016/j.mcna.2022.12.003.
Chen, L. K. et al. Asian Working Group for Sarcopenia: 2019 Consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 21, 300–307 (2020). https: //doi.org/10.1016/j.jamda.2019.12.012.
Wu, T.-L., Huang, C.-W. & Yen, H.-H. Prevalence of fatty liver disease: a Taiwanese ultrasound cohort-based study. Ultrasound Med. Biol. 2024, https: //doi.org/10.1016/j.ultrasmedbio.2024.01.064.
Singhai, A., Yadav, V., Joshi, R., Malik, R., B. T., S. & Kamle, S. Prevalence, metabolic profile, and associated risk factors of non-alcoholic fatty liver disease in an adult population of India. Cureus. 2023, https: //doi.org/10.7759/cureus.33977.
Kirk, B. et al. The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing53, afae052 (2024). https: //doi.org/10.1093/ageing/afae052.
Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet. 393, 2636–2646 (2019). https: //doi.org/10.1016/S0140-6736(19)31138-9.
Iwaki, M. et al. Impact of sarcopenia on non-alcoholic fatty liver disease. Nutrients. 15, 891 (2023). https: //doi.org/10.3390/nu15040891.
Petermann-Rocha, F., Balntzi, V., Gray, S. R., Lara, J. & Celis-Morales, C. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle. 2021, https: //doi.org/10.1002/jcsm.12783.
Shaikh, N., Harshitha, R. & Bhargava, M. Prevalence of sarcopenia in an elderly population in rural South India: a cross-sectional study. F1000Res. 2020, https: //doi.org/10.12688/f1000research.22580.1.
Giri, S., Anirvan, P. & Lavekar, A. Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease. World J. Gastrointest. Pathophysiol. 15, 91–100 (2024). https: //doi.org/10.4291/wjgp.v15.i1.91100.
Joo, S. K. & Kim, W. I. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2022, https: //doi.org/10.3350/cmh.2022.0358.
Roh, E. et al. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study. Hepatol. Int. 2021, https: //doi.org/10.1007/s12072-021-10258-8.
Harring, M. A. et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis. Clin. Gastroenterol. Hepatol. 2023, https: //doi.org/10.1016/j.cgh.2023.02.013.
Chakravarthy, M. V., Siddiqui, M. S., Forsgren, M. & Sanyal, A. J. Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis. Front. Endocrinol. 2020, https: //doi.org/10.3389/fendo.2020.592373.
Xia, L. et al. Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med. 9, 7964–7978 (2020). https: //doi.org/10.1002/cam4.3428.
Bogucka, A., Kopiczko, A. & Charzewska, J. Sarcopenia: prevalence and its main risk factors in older women. Anthropol. Rev. 86, (2023). https: //doi.org/10.18778/1898-6773.86.1.05.
Tokumasu, K., Matsuki, N., Fujikawa, H., Sakamoto, Y. & Otsuka, F. Reliability and validity of the Japanese version of the fatigue assessment scale. Intern. Med. 2024, https: //doi.org/10.2169/internalmedicine.4101-24.
Chung, S. M., Moon, J. S. & Chang, M. C. Prevalence of sarcopenia and its association with diabetes: a meta-analysis of the community-dwelling Asian population. Front. Med. China. 2021, https: //doi.org/10.3389/fmed.2021.681232.
Chen, L. K. et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 21, 300–307.e2 (2020). https: //doi.org/10.1016/j.jamda.2019.12.012.
Wu, X., Li, X., Xu, M., Zhang, Z., He, L. & Li, Y. Sarcopenia prevalence and associated factors among older Chinese population: findings from the China Health and Retirement Longitudinal Study. PLoS One. 2021, https: //doi.org/10.1371/journal.pone.0247617.
Charan, J. et al. Sample size calculation in medical research: a primer. Ann. Natl. Acad. Med. Sci. (India). 57, 74–80 (2021). https: //doi.org/10.1055/s-0040-1722104.
Zhang, L. et al. Role of physical performance measures for identifying functional disability among Chinese older adults: data from the China Health and Retirement Longitudinal Study. PLoS One. 14, e0215693 (2019). https: //doi.org/10.1371/journal.pone.0215693.
Zhang, Y. et al. A novel method for identifying frailty and quantifying MS using the six-minute walking test. Sensors. 24, 4489 (2024). https: //doi.org/10.3390/s24144489.
V., S., Kanat, B. B. & Yavuzer, H. Fatigue and primary sarcopenia in geriatric patients. Rev. Assoc. Med. Bras. 68, 1565–1570 (2022). https: //doi.org/10.1590/1806-9282.20220662.
Şenoymak, İ., Eğici, M. T. & Şenoymak, M. C. Sarcopenia and associated factors in adults aged 40 and above: a study conducted in primary healthcare. Cureus. 2024, https: //doi.org/10.7759/cureus.67618.
Yang, L., Smith, L. & Hamer, M. Gender-specific risk factors for incident sarcopenia: 8-year follow-up of the English longitudinal study of ageing. J. Epidemiol. Community Health. 2019, https: //doi.org/10.1136/jech-2018-211258.
Hwang, J. & Park, S. W. Sex differences of sarcopenia in an elderly Asian population: the prevalence and risk factors. Int. J. Environ. Res. Public Health. 19, 11980 (2022). https: //doi.org/10.3390/ijerph191911980.
Berriche, O. et al. Sarcopenia prevalence and risk factors in obese Tunisian adults. Tunisie Med. 102, 4965 (2024). https: //doi.org/10.62438/tunismed.v102i8.4965.
Barazzoni, R. et al. Sarcopenic obesity: time to meet the challenge. Obes. Facts. 11, 294–305 (2018). https: //doi.org/10.1159/000490361.
Jeong, S. H. et al. Association between sarcopenia level and metabolic syndrome. PLoS One. 16, e0248856 (2021). https: //doi.org/10.1371/journal.pone.0248856.
Roh, E. et al. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study. Hepatol. Int. 16, 545–554 (2022). https: //doi.org/10.1007/s12072-021-10258-8.
Lino, V. T. S., Rodrigues, N. C. P., O’Dwyer, G., Andrade, M. K. d. N., Mattos, I. E. & Portela, M. C. Handgrip strength and factors associated in poor elderly assisted at a primary care unit in Rio de Janeiro, Brazil. PLoS One. 11, e0166373 (2016). https: //doi.org/10.1371/journal.pone.0166373.
Pratt, J. et al. Grip strength performance from 9431 participants of the GenoFit study: normative data and associated factors. Geroscience. 43, 2533–2546 (2021). https: //doi.org/10.1007/s11357-021-00410-5.
Ballesteros-Pomar, M. D. et al. Disease-related malnutrition and sarcopenia predict worse outcomes in medical inpatients: a cohort study. Nutrients. 13, 2937 (2021). https: //doi.org/10.3390/nu13092937.
Kamper, R. S. et al. Associations between inflammatory markers, body composition, and physical function: the Copenhagen Sarcopenia Study. J. Cachexia Sarcopenia Muscle. 12, 1641–1652 (2021). https: //doi.org/10.1002/jcsm.12832.
Schene, M. R. et al. Physical performance and sarcopenia assessment in patients with a recent fracture visiting the fracture liaison service. Osteoporos. Int. 35, 851–862 (2024). https: //doi.org/10.1007/s00198-023-07009-w.
Xia, X., Xiang, S., Hua, L., Sun, Q. & Wang, R. The relationship between lifestyles and sarcopenia-related traits: a two-sample Mendelian randomization study. Arch. Gerontol. Geriatr. 116, 105169 (2024). https: //doi.org/10.1016/j.archger.2023.105169.
Abiri, B. & Vafa, M. Nutrition and sarcopenia: a review of the evidence of nutritional influences. Crit. Rev. Food Sci. Nutr. 2019, https: //doi.org/10.1080/10408398.2017.1412940.
Yun, Y., Wang, C., Ding, Y., He, J. & Lv, Y. Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: analysis of the National Health and Nutrition Examination Survey III. Front. Endocrinol. 2023, https: //doi.org/10.3389/fendo.2023.1101892.
Copyright (c) 2025 Amerta Nutrition
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
AMERTA NUTR by Unair is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
